NASDAQFinancialsInsurance - SpecialtySnapshot 2026-10-23
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
A matching fiscal period and sufficient coverage are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Successful integration of Fortegra acquisition | A primary condition in Tiptree, Inc.'s published investment case. The stated target is complete integration and synergy realization by end 2026. | Improving | acquisition integration delays or failures reported in 2026 | Integration completed May 2026 vs end-2026 target Fortegra acquisition closed May 29, 2026. New USI deal announced July 2026. No integration issues reported. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Maintain dividend at $0.06 per share | The company maintains a steady dividend of $0.06 per share. | Intact | dividend per share falls below $0.06 in next 4 quarters | Dividend per share: $0.06 per share FY2026-Q2; GAAP. Published target: >=0.06 USD per share. Target period is not explicitly aligned with this observation. Source published Jul 29, 20260.06 USD/share · source valueSource reportLast status assessment Oct 24, 2026Measurement sourceconsolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 0278eec9-4672-465d-9efd-52564ffab5de. Source status: eligible. Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 4 of last 4 quarters. The company consistently declared and paid a dividend of $0.06 per share from 2025-Q3 through 2026-Q2. This recurring commitment is maintained steadily, matching management's stated priority. Delivery assessment Oct 24, 2026 |
Revenue above $540 million in 2025 | Revenue is expected above $540 million in 2025. | Intact | revenue falls below $540 million in FY25 | Revenue: $0 FY2026-Q2; GAAP. Published target: >=540.3 USD_MILLIONS. Target period is not explicitly aligned with this observation. Source published Jul 29, 20260 USD · source valueSource reportLast status assessment Oct 24, 2026Measurement sourceconsolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q2. Source status: unverified. Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Maintain valuation discount to peers | Its valuation is cheap compared to peers with a P/E of 12.8 versus 15.3. | Intact | P/E rises above 15 without earnings growth | P/E (TTM): 19.16x As of 2026-10-23; trailing twelve months. The target timing and basis require a separate assessment. Market data as of Oct 23, 202619.1625 ratio · calculatedLast status assessment Oct 24, 2026Measurement sourceconsolidated · TTM valuation Period ending Oct 23, 2026 Source: mart.stock_valuation_daily. Reference: TIPT:2026-10-23. Source status: canonical calculation. Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
Compare these dated observations with the operating requirements above
Comparable estimate history is unavailable.
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Compare required revenue and earningsMonthly analyst history is unavailable.
Recent actions · Sep 25–Oct 24 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Oct 30, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earnings3 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a value-oriented financial company with a potential growth initiative, rather than a proven durable compounder. Its multi-year thesis is in a watch state: recent financial performance is weak, management is rated volatile, and the evidence snapshot has low overall confidence.
TIPT is described as cheap versus peers, while the priced-in tag is justified and fragility is low. The expectations gap is negative, so the evidence does not suggest the valuation reflects a clear cushion against disappointment.
Near term, recent performance sits well below its industry cohort, and earnings surprises have been erratic, though the stated miss-risk tier is quiet. Over the multi-year view, the $100 million Universal Shield acquisition could help rebuild a specialty-insurance platform, while the steady dividend and repurchases show continued capital deployment; the acquisition is new and its execution status is mixed.
The near-term case would weaken if management cuts guidance or if rate cuts weigh on financial companies. Sector momentum could help if bellwethers FNF, FAF, and ACT continue to report strong earnings and raise guidance. Over the multi-year view, the key question is whether TIPT can complete the acquisition and develop a scalable specialty-insurance platform.
TIPT’s 1-to-3-year view combines peer-relative cheapness with weak recent results, volatile management, and an unproven strategic expansion. The thesis depends on execution and sector conditions, and confidence remains low. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.